In 2020, both the U.S. Food and Drug Administration and the European Medicine Agency approved the second-generation anti-CD19 CAR T cell products axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel, formerly known as CTL019) for clinical use against diffuse large B cell lymphoma (DLBCL) and B-ALL but not CLL. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.